2-(4-hydroxyphenyl)-6-methoxy-4-methylbenzoxazole | 440122-61-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-hydroxyphenyl)-6-methoxy-4-methylbenzoxazole
• 英文别名: 4-(6-methoxy-4-methyl-1,3-benzoxazol-2-yl)phenol
• CAS: 440122-61-2
• 化学式: C₁₅H₁₃NO₃
• 分子量: 255.273
• InChiKey: JEBBSUOWKQPULZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  55.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-hydroxyphenyl)-6-methoxy-4-methylbenzoxazole 、 2-amino-5-methoxy-3-methyl-phenol 以was obtained the title compound (340 mg) as a light orange solid的产率得到6-Hydroxy-2-(4-hydroxyphenyl)-4-methylbenzoxazole
  参考文献：
  名称：

  Therapeutic compounds

  摘要：

  描述了化学式(I)的化合物，用作雌激素受体-β-选择性配体，其中：X为O或S；R1，R3R6如规范中所述。描述了在治疗阿尔茨海默病、焦虑症、抑郁症、骨质疏松症、心血管疾病、类风湿性关节炎和前列腺癌中使用这些化合物的方法，以及制造它们的过程。

  公开号：

  US20040102435A1

文献信息

• Therapeutic benzothiazole compounds
  申请人：Barlaam Bernard

  公开号：US20060111408A1

  公开（公告）日：2006-05-25

  Compounds of the formula (I) for use as an estrogen receptor -β-selective ligand are described wherein: X is O or S; and R 1 , R 3 -R 6 are as described in the specification. The use of these compounds in treating Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer is described; as are processes for making them.

  本文描述了化学式（I）的化合物，可用作雌激素受体-β选择性配体，其中X为O或S；R1、R3-R6如规范中所述。描述了在治疗阿尔茨海默病、焦虑症、抑郁症、骨质疏松症、心血管疾病、类风湿性关节炎和前列腺癌方面使用这些化合物的方法，以及制备它们的过程。
• ER-beta-selective ligands
  申请人：Barlaam Bernard

  公开号：US20070208066A1

  公开（公告）日：2007-09-06

  Compounds of the formula (I) for use as an estrogen receptor -β-selective ligand are described wherein: X is O or S; and R 1 , R 3 -R 6 are as described in the specification. The use of these compounds in treating Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer is described; as are processes for making them.

  本文描述了化学式（I）的化合物，用作雌激素受体-β选择性配体，其中X为O或S；R1，R3-R6如规范所述。描述了在治疗阿尔茨海默病，焦虑症，抑郁症，骨质疏松症，心血管疾病，类风湿性关节炎和前列腺癌方面使用这些化合物的方法，以及制造它们的过程。
• THERAPEUTIC COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1345914A1

  公开（公告）日：2003-09-24
• US7045539B2
  申请人：——

  公开号：US7045539B2

  公开（公告）日：2006-05-16
• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSES THERAPEUTIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2002051821A1

  公开（公告）日：2002-07-04

  Compounds of the formula (I) for use as an estrogen receptor -β-selective ligand are described wherein: X is O or S; and R?1, R3 R6¿ are as described in the specification. The use of these compounds in treating Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer is described; as are processes for making them.